IBDEI1ED ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22345,1,4,0)
 ;;=4^A60.01
 ;;^UTILITY(U,$J,358.3,22345,2)
 ;;=^5000353
 ;;^UTILITY(U,$J,358.3,22346,0)
 ;;=A60.04^^102^1141^123
 ;;^UTILITY(U,$J,358.3,22346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22346,1,3,0)
 ;;=3^Herpetic Vulvovaginitis
 ;;^UTILITY(U,$J,358.3,22346,1,4,0)
 ;;=4^A60.04
 ;;^UTILITY(U,$J,358.3,22346,2)
 ;;=^5000356
 ;;^UTILITY(U,$J,358.3,22347,0)
 ;;=B01.9^^102^1141^120
 ;;^UTILITY(U,$J,358.3,22347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22347,1,3,0)
 ;;=3^Herpes, varicella
 ;;^UTILITY(U,$J,358.3,22347,1,4,0)
 ;;=4^B01.9
 ;;^UTILITY(U,$J,358.3,22347,2)
 ;;=^5000487
 ;;^UTILITY(U,$J,358.3,22348,0)
 ;;=B00.3^^102^1141^119
 ;;^UTILITY(U,$J,358.3,22348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22348,1,3,0)
 ;;=3^Herpes, Meningitis
 ;;^UTILITY(U,$J,358.3,22348,1,4,0)
 ;;=4^B00.3
 ;;^UTILITY(U,$J,358.3,22348,2)
 ;;=^5000470
 ;;^UTILITY(U,$J,358.3,22349,0)
 ;;=B00.9^^102^1141^116
 ;;^UTILITY(U,$J,358.3,22349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22349,1,3,0)
 ;;=3^Herpes NEC
 ;;^UTILITY(U,$J,358.3,22349,1,4,0)
 ;;=4^B00.9
 ;;^UTILITY(U,$J,358.3,22349,2)
 ;;=^5000480
 ;;^UTILITY(U,$J,358.3,22350,0)
 ;;=B39.2^^102^1141^127
 ;;^UTILITY(U,$J,358.3,22350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22350,1,3,0)
 ;;=3^Histoplasmosis,Pulmonary
 ;;^UTILITY(U,$J,358.3,22350,1,4,0)
 ;;=4^B39.2
 ;;^UTILITY(U,$J,358.3,22350,2)
 ;;=^5000634
 ;;^UTILITY(U,$J,358.3,22351,0)
 ;;=B39.9^^102^1141^125
 ;;^UTILITY(U,$J,358.3,22351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22351,1,3,0)
 ;;=3^Histoplasmosis NEC
 ;;^UTILITY(U,$J,358.3,22351,1,4,0)
 ;;=4^B39.9
 ;;^UTILITY(U,$J,358.3,22351,2)
 ;;=^5000638
 ;;^UTILITY(U,$J,358.3,22352,0)
 ;;=Z21.^^102^1141^105
 ;;^UTILITY(U,$J,358.3,22352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22352,1,3,0)
 ;;=3^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,22352,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,22352,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,22353,0)
 ;;=B20.^^102^1141^104
 ;;^UTILITY(U,$J,358.3,22353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22353,1,3,0)
 ;;=3^HIV + (Symptomatic)/AIDS
 ;;^UTILITY(U,$J,358.3,22353,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,22353,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,22354,0)
 ;;=A63.0^^102^1141^129
 ;;^UTILITY(U,$J,358.3,22354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22354,1,3,0)
 ;;=3^Human Papillomavirus infection
 ;;^UTILITY(U,$J,358.3,22354,1,4,0)
 ;;=4^A63.0
 ;;^UTILITY(U,$J,358.3,22354,2)
 ;;=^5000360
 ;;^UTILITY(U,$J,358.3,22355,0)
 ;;=Z91.19^^102^1141^128
 ;;^UTILITY(U,$J,358.3,22355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22355,1,3,0)
 ;;=3^History of past non-compliance
 ;;^UTILITY(U,$J,358.3,22355,1,4,0)
 ;;=4^Z91.19
 ;;^UTILITY(U,$J,358.3,22355,2)
 ;;=^5063618
 ;;^UTILITY(U,$J,358.3,22356,0)
 ;;=T85.79XA^^102^1141^130
 ;;^UTILITY(U,$J,358.3,22356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22356,1,3,0)
 ;;=3^Infect/inflm reaction d/t implantable device graft,init encntr
 ;;^UTILITY(U,$J,358.3,22356,1,4,0)
 ;;=4^T85.79XA
 ;;^UTILITY(U,$J,358.3,22356,2)
 ;;=^5055676
 ;;^UTILITY(U,$J,358.3,22357,0)
 ;;=J11.00^^102^1141^133
 ;;^UTILITY(U,$J,358.3,22357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22357,1,3,0)
 ;;=3^Influenza with unspecified type of pneumonia
 ;;^UTILITY(U,$J,358.3,22357,1,4,0)
 ;;=4^J11.00
 ;;^UTILITY(U,$J,358.3,22357,2)
 ;;=^5008156
 ;;^UTILITY(U,$J,358.3,22358,0)
 ;;=B82.9^^102^1141^136
